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Abstract ADP acts as an agonist of platelet aggregation via
specific receptors which are still to be characterised. Amplifica-
tion by PCR of a human platelet cDNA library confirmed the
presence of mRNA of the P2Y1 receptor in platelets. In order to
determine if these P2Y1 receptors were involved in ADP-induced
platelet activation, we determined the effects of A3P5PS, an
antagonist of the P2Y1 receptor, on the binding of [33P]2-MeS-
ADP, a potent analogue of ADP. We found that A3P5PS
displaced about 27% of [33P]2-MeS-ADP binding, a receptor
population which has been shown to be resistant to treatment
with clopidogrel, a selective anti-ADP agent. A3P5PS specifi-
cally inhibited 2-MeS-ADP-induced shape change and calcium
increase but did not affect adenylyl cyclase down-regulation. 2-
MeS-ADP-induced platelet aggregation was also inhibited by
A3P5PS but was restored when platelets were further activated
by serotonin, a non-aggregating compound, therefore suggesting
that P2Y1-mediated stimulation is an absolute prerequisite for
ADP to induce platelet aggregation and a key event for platelet
activation and aggregation to occur. These results therefore show
that ADP-induced aggregation cannot be attributed to activation
of P2Y1 alone, but must be attributed to the simultaneous
activation of the high affinity receptor (P2Y1) and a low affinity
receptor of ADP (still to be discovered), each of them essential,
but neither able to trigger aggregation alone.
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1. Introduction
Adenosine diphosphate (ADP) is the oldest known platelet
agonist but the way by which it activates platelets is still not
totally understood and, even if it is admitted that it acts on
platelets via speci¢c receptors, these receptors have not been
characterised and cloned. Progress in the knowledge of ADP-
induced events in platelets has been made essentially because
of the use of a selective ADP-blocking agent clopidogrel [1].
This new drug has been recently demonstrated to be e⁄ca-
cious in preventing thrombotic events in atherosclerotic pa-
tients [2]. Several studies, performed with clopidogrel in di¡er-
ent species including rat, rabbit and human, have
demonstrated that it antagonised the binding of ADP on its
platelet receptors and consequently inhibited speci¢cally
ADP-induced aggregation [3].
Although the exact nature of the purinoceptor responsible
for ADP-induced platelet aggregation is still unknown, several
purinoreceptors have been described in many other cells. This
receptor family, named P2, is at present composed of 14 dif-
ferent cloned receptors classi¢ed into two subfamilies : P2X
(seven members) are pore-forming protein sequences and
P2Y (seven members) are G-protein-coupled receptors [4].
Platelet ADP receptors (named P2T) which have not yet
been cloned have been classi¢ed in the P2Y subfamily. In
contrast with the other P2 receptors, diphosphate derivatives
of adenosine act as agonists whereas the corresponding tri-
phosphates behave as antagonists [5]. In a recent paper, LeŁon
et al. demonstrated the presence of one of these P2 receptors
(P2Y1) in platelets [6] and suggested that it could be the ‘un-
known’ P2T, responsible for the ADP-induced aggregation of
platelets. However, up to now, this provocative observation
has not been con¢rmed and most importantly, it is still un-
known whether this receptor is the target of clopidogrel : the
‘‘low a⁄nity ADP receptor responsible for platelet aggrega-
tion’’ [7] or another purinoceptor responsible for other func-
tions of ADP on platelets such as shape change.
Our work was therefore aimed at determining if the P2Y1
purinoceptor is the receptor responsible for ADP-induced
platelet aggregation and the target of clopidogrel.
2. Materials and methods
2.1. Construction of a human platelet cDNA library
Human platelets (obtained from 72 units of outdated platelet con-
centrates) (Centre de Transfusion Sanguine, Toulouse, France) were
puri¢ed by repeated centrifugation on Ficoll Paque (Pharmacia, Upp-
sala, Sweden) and washes in phosphate-bu¡ered saline (PBS). Total
RNA was extracted from frozen platelet pellets (1012 platelets) with
guanidinium thiocyanate lysis followed by ultracentrifugation in a
cesium chloride solution as described by Sambrook et al. [8]. About
5 Wg of polyA mRNA was ¢nally extracted from the total RNA
suspension using the Fast Track kit (Invitrogen, Leek, The Nether-
lands).
Double-strand platelet cDNAs were obtained from 5 Wg of human
platelet mRNA using the Superscript Plasmid System for cDNA Syn-
thesis and Plasmid Cloning kit (Gibco-BRL, Cergy Pontoise, France).
After synthesis, ligation of BstXI adapters and digestion with NotI as
described in the kit, cDNAs were size-fractionated on a 1% agarose
gel using the Geneclean II kit (Bio 101, La Jolla, CA, USA). 40 ng of
cDNAs migrating above 1000 bp was ligated (16 h at 16‡C using
4 units T4 DNA ligase) with 200 ng of a BstXI-NotI linearised
pZeo-SV vector (Invitrogen) in which the HindIII-XhoI fragment of
the polylinker had been replaced by the HindIII-XhoI fragment of the
pCDNA3 vector (Invitrogen). The ligation reaction was ethanol-pre-
cipitated together with 20 Wg of yeast tRNA, resuspended in 20 Wl
water, and electroporated in 10U40 Wl of Electromax DH 10B (E. coli
strain provided by Gibco-BRL). After each shock, 1 ml of SOC me-
dium was immediately added, and the 10 ml resulting suspension was
incubated for 1 h at 37‡C with a 225 rpm shaking. Cells were then
plated on 20 low salt bu¡er (LSB) plates containing 25 Wg/ml zeocyn
and left to grow overnight at 37‡C. The 2U106 resulting clones were
¢nally pooled in 200 ml LSB containing 20% glycerol, aliquoted and
kept frozen at 380‡C.
2.2. PCR of the platelet P2Y1 receptor
PCR was performed on a human platelet cDNA library as de-
scribed by Bouaboula et al. [9]. Sample was ampli¢ed by 35 repeated
cycles at 95‡C for 1 min, 56‡C for 1 min, and 72‡C for 2.2 min. PCR
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reaction mixture (total volume 50 Wl) contained 2 U of Taq DNA
polymerase (Perkin-Elmer Cetus, Saint Quentin en Yvelines, France)
with 10 pmol of the following primers: 5PAAG TCG AGG AGG
AGA GAA TG-3P and 5P-GGA AGA GAG ACT GTG AAA GC-
3P. These primers spanned a 1332 bp sequence containing the P2Y1
CDS. The PCR product was analysed by agarose electrophoresis and
sequenced.
2.3. ADP receptor-related studies on rabbit platelets
Platelets were obtained from female New Zealand rabbits (2.5^3.0
kg, Lago, France) treated with a single oral administration of clopi-
dogrel (25 mg/kg, p.o.) (Sano¢ Recherche, Toulouse, France). Two
hours after the administration of clopidogrel or the vehicle, blood was
withdrawn into a 3.8% trisodium citrate solution (1:9 volumes of
blood) and centrifuged at 180Ug for 10 min to prepare platelet-rich
plasma (PRP).
Platelet aggregation was monitored by the turbidimetric method of
Born [10] on a dual-channel Chrono-Log aggregometer. PRP diluted
twofold in saline was equilibrated at 37‡C for 1 min under constant
stirring (900 rpm) in the presence or absence of adenosine 3P-phos-
phate-5-phosphosulphate (A3P5PS, Sigma, L’Ile d’Abeau, France),
and aggregation was induced by various agonists, including 2-meth-
ylthio-ADP (2-MeS-ADP, Bioblok, Illkirch, France), serotonin (5-
HT, Sigma) and ADP (Biopool, Umeaî, Sweden). Shape change was
measured according to Colman et al. [11]. Brie£y, PRP (200 Wl) di-
luted in 200 Wl Tyrode bu¡er was incubated for 2 min in an aggreg-
ometer under constant stirring (900 rpm) at 37‡C. Then, 4 Wl EDTA
(500 mM) was added and 10 s later, shape change was induced by the
tested compounds. When tested, A3P5PS was added 30 s before
EDTA. Aggregation and shape change were estimated quantitatively
by measuring the maximum deviation above baseline level.
For measurement of adenylyl cyclase activity, PRP was diluted in
the same volume of bu¡er containing 15 mM Tris, 120 mM NaCl,
4 mM KCl, 1.6 mM MgSO4, 2 mM NaH2PO4, 10 mM glucose and
1.5 mM IBMX (Sigma), pH 7.4 at 37‡C. Three minutes after adenylyl
cyclase activation by 10 Wl PGl2 (Sigma), 500 Wl samples were incu-
bated for 3 min with 2.5 WM ADP or 25 nM 2-MeS-ADP, in the
presence or absence of 250 WM A3P5PS. The reaction was stopped
by adding 50 Wl 6 N HCl and 50 Wl 0.2 M EDTA and boiling for
5 min. Cyclic AMP was extracted according to Meurs et al. [12] and
cAMP in the samples was measured by an assay kit (Amersham,
Amersham, UK).
For cytosolic free calcium measurements, platelets were washed and
resuspended in bu¡er PSS (NaCl 145 mM, KCl 5 mM, MgCl2 1 mM,
glucose 5.6 mM, HEPES/NaOH 5 mM pH 7.4), containing BSA
0.35%, apyrase 0.1 U/ml, hirudin 1 U/ml (PSSA) and incubated at
37‡C for 40 min with fura-2/AM (10 WM). The platelet suspension was
washed once with PSSA containing 1 WM PGI2 to remove extracel-
lular fura-2. Platelets were then resuspended in PSSA at 3U108/ml,
and kept in the dark at room temperature. Experiments were carried
out under constant stirring in a PTI spectro£uorometer using 30 Wl of
cell suspension diluted in 3 ml PSS containing 1 mM CaCl2 in a
£uorescence cuvette at 37‡C. Cytosolic free calcium was estimated
as the £uorescence ratio R = F340/F380 (where F340 and F380 are the
£uorescence intensities of fura-2 measured at 510 nm after excitation
at 340 nm and 380 nm respectively) as described by Grynkiewicz et al.
[13].
Binding of [33P]2-MeS-ADP (NEN) to rabbit platelets was meas-
ured as previously described by us [14] in a total volume of 0.2 ml of
fourfold diluted PRP in Tyrode bu¡er. Triplicate incubations were
carried out at 4‡C for 15 min in the presence of 0.1 WCi of labelled
ligand and di¡erent concentrations of the tested compounds. The
reaction was terminated by the addition of a 3 ml ice-cold assay bu¡er
followed by rapid vacuum ¢ltration over glass-¢bre ¢lters (Filtermats
11734, Skatron Instruments Inc., Sterling, USA). Filters were then
washed twice with 5 ml ice-cold incubation bu¡er, dried and the
radioactivity measured by scintillation counting.
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Fig. 1. E¡ect of A3P5PS on the binding of [33P]2-MeS-ADP to rab-
bit platelets. Platelets from rabbits treated with clopidogrel (25 mg/
kg, 2 h) (E) or with the vehicle (a) were incubated for 15 min at
4‡C with [33P]2-MeS-ADP (0.5 nM) in the presence of increasing
concentrations of A3P5PS. Bound ligand was then separated from
free ligand as described in Section 2. Binding is expressed as a per-
centage of the speci¢c binding in control platelets, from triplicate
measurements.
Fig. 2. E¡ect of A3P5PS on the displacement of [33P]2-MeS-ADP to
rabbit platelets by ADP. Platelets from rabbits treated with clopi-
dogrel (25 mg/kg, 2 h) (F, E) or with the vehicle (b, a) were incu-
bated for 15 min at 4‡C with [33P]2-MeS-ADP (0.5 nM) and in-
creasing concentrations of ADP, in the presence (closed symbols) or
absence (open symbols) of 250 WM A3P5PS. Each point is the mean
of triplicate measurements.
Fig. 3. E¡ect of A3P5PS on 2-MeS-ADP-induced activation of rab-
bit platelets. Shape change (F), cytosolic calcium increase (S), ad-
enylyl cyclase down regulation (R) and aggregation (b) induced by
25 nM 2-MeS-ADP were measured in the presence of various con-
centrations of A3P5PS, as described in Section 2. Results (means of
triplicate measurements) are expressed as inhibition of the e¡ects
obtained in the absence of A3P5PS.
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3. Results and discussion
Ampli¢cation by PCR on our human platelet cDNA library
with speci¢c primers for the P2Y1 gene produced only one
band at the expected size (1332 bp). Sequencing revealed that
this band was homologous to the P2Y1 cDNA, a gene already
found in human tissues including prostate, ovary, intestine,
placenta and HEL cells [15^17]. This result therefore con¢rms
and extends that indeed, as shown by LeŁon et al. [6], mRNA
encoding the P2Y1 receptor is present in platelets.
In order to determine if the P2Y1 receptor expressed in
platelets was involved in ADP-induced platelet activation,
we determined the e¡ects of A3P5PS, a speci¢c antagonist
of the P2Y1 receptor [18] on the binding of [33P]2-MeS-
ADP. This ligand has been shown to bind to two di¡erent
types of ADP receptors present on the surface of rat platelets
[7] : a high a⁄nity ADP binding site (Ki = 15 nM), responsible
for shape change which represented about 30% of the total
binding of ADP, and a low a⁄nity ADP site (Ki = 486 nM)
(about 70% of the total binding sites) responsible for adenylyl
cyclase down-regulation and platelet aggregation. A3P5PS
displaced about 27% of [33P]2-MeS-ADP binding with an
IC50 value of 69 WM (Fig. 1), indicating that the P2Y1 recep-
tors only represent one fourth of the total [33P]2-MeS-ADP
binding sites on platelets. This ¢nding was con¢rmed when we
compared the displacement of [33P]2-MeS-ADP binding by
ADP in the presence or absence of 250 WM A3P5PS (Fig. 2)
where two di¡erent binding sites for ADP were observed in
control rabbit platelets (IC50 = 5 and 875 nM). Incubation
with A3P5PS strongly decreased the high a⁄nity site (82%
inhibition) but did not a¡ect the binding of [33P]2-MeS-
ADP to the low a⁄nity ADP sites (Fig. 2).
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Fig. 4. E¡ect of 5-HT on the inhibition of 2-MeS-ADP e¡ects by A3P5PS in rabbit platelets. Shape change (A), calcium in£ux (B) and aggre-
gation (C), recorded as described in Section 2, were induced by 2.5 WM 5-HT (lane 1) or 25 nM 2-MeS-ADP (lane 2). In lane 3, A3P5PS (250
WM) was incubated before activation by 25 nM 2-MeS-ADP, then 2.5 WM 5-HT was added.
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Work from our group showed that clopidogrel only a¡ects
the binding of [33P]2-MeS-ADP to its low a⁄nity sites and
does not a¡ect the interaction between [33P]2-MeS-ADP and
its high a⁄nity receptors [7]. These ‘clopidogrel-resistant’ re-
ceptors are responsible for ADP-induced shape change, an
event which has been shown not to be a¡ected by this com-
pound [7]. This ‘clopidogrel-resistant’ [33P]2-MeS-ADP bind-
ing was totally displaced by A3P5PS (IC50 = 41 WM) (Fig. 1),
indicating that this class of receptors corresponds to the P2Y1
receptors present on the platelet surface.
Activation of the ADP receptors by ADP or 2-MeS-ADP is
followed by several changes in platelets including shape
change [19], cytosolic calcium increase [20], adenylyl cyclase
down-regulation [21], protein phosphorylation [22,23], Gp
IIb-IIIa activation [24] and aggregation [10]. Some of them
(adenylyl cyclase down-regulation, Gp IIb-IIIa activation, ag-
gregation and some phosphorylations) are inhibited by clopi-
dogrel treatment indicating that they are the consequence of
activation of the low a⁄nity binding site [7,23]. ADP-induced
shape change, calcium increase, MLCK and PKC activation,
attributed to activation of the high a⁄nity ADP binding sites,
have been shown not to be a¡ected by clopidogrel treatment
[7,23].
The observation that P2Y1 was the clopidogrel-resistant,
high a⁄nity binding site of ADP was con¢rmed by the e¡ect
of A3P5PS which speci¢cally inhibited 2-MeS-ADP-induced
shape change and calcium increase (Fig. 3). On the other
hand, adenylyl cyclase down-regulation, which was previously
attributed by us to activation of the low a⁄nity ADP recep-
tors [7], was not a¡ected by A3P5PS (Fig. 3). Surprisingly, 2-
MeS-ADP-induced platelet aggregation was also inhibited by
A3P5PS but the full aggregating activity of 2-MeS-ADP was
restored in A3P5PS-treated platelets when platelets were fur-
ther activated with 5-HT, a non-aggregant agonist (Fig. 4).
Similar results were obtained with ADP instead of 2-MeS-
ADP (not shown), suggesting that P2Y1-mediated stimulation
is an absolute prerequisite for ADP to induce platelet aggre-
gation.
This work therefore demonstrates for the ¢rst time that the
P2Y1 purinoceptor is involved in ADP-induced shape change
and calcium increase. However, the inhibition of ADP-in-
duced aggregation observed with A3P5PS indicates that
P2Y1 stimulation is a key event for platelet activation and
aggregation to occur. The anti-aggregating activity of clopi-
dogrel and its selective antagonism of the low a⁄nity ADP
receptors further demonstrate the involvement of another
pathway of platelet activation, triggered by the low a⁄nity
ADP receptors. A double pathway of platelet activation was
¢rst suggested by some authors who studied the potentiation
of epinephrine by 5-HT, low concentrations of ADP or pro-
tein kinase C activation [25,26]. In these experiments, the au-
thors showed that platelet aggregation was the result of di¡er-
ent activation pathways acting in synergy [25,26]. Our results
indicate that this scenario can also be applied to the ADP
activation pathway.
Among the P2Y1-related events, cytosolic calcium increase
seems to be a major event for aggregation, whereas shape
change has been demonstrated not to be required [27]. Several
enzymatic systems, mainly protein phosphokinases, are
known to be calcium-regulated and cytosolic calcium increase
has been considered as a necessary but not su⁄cient event in
the platelet aggregation process [28].
Therefore, from the results shown in this paper, it is clear
that ADP-induced aggregation cannot be attributed to activa-
tion of the P2Y1 alone, but must be attributed to the simul-
taneous activation of the high a⁄nity receptor (P2Y1) and the
low a⁄nity receptor of ADP (not known), both of them es-
sential but neither able to trigger aggregation alone. This oth-
er ADP receptor, which is clopidogrel-sensitive, has still to be
identi¢ed. In a recent paper, we demonstrated that P2X1,
which is present on rat platelets, was not involved in the
aggregation process, nor antagonised by clopidogrel treatment
[29], and therefore was not the low a⁄nity ADP receptor.
Like the high a⁄nity receptor (P2Y1), the low a⁄nity recep-
tor could be a seven transmembrane domain receptor, coupled
to G-proteins as suggested by its ability to regulate adenylyl
cyclase through a Gi protein [30].
In conclusion, one platelet ADP receptor involved in the
ADP-induced aggregation (shape change) has been found, but
the other one, which is the target of clopidogrel, co-respon-
sible for the aggregating activity of ADP, has still to be dis-
covered.
References
[1] Herbert, J.M., Frehel, D., ValleŁe, E., Kie¡er, G., Gouy, D.,
Berger, Y., Necciari, J., Defreyn, G. and Ma¡rand, J.P. (1993)
Cardiovasc. Drug Rev. 11, 180^198.
[2] CAPRIE Steering Committee (1996) Lancet 348, 1329^1339.
[3] Savi, P. and Herbert, J.M. (1996) Med. Res. Rev. 16, 159^179.
[4] Fredholm, B.B., Abbracchio, M.P., Burnstock, G., Dubyak,
G.R., Harden, T.K., Jacobson, K.A., Schwabe, U. and Williams,
M. (1997) Trends Pharmacol. Sci. 18, 79^82.
[5] Mills, D.C.B. (1996) Thromb. Haemost. 76, 835^856.
[6] LeŁon, C., Hechler, B., Vial, C., Leray, C., Cazenave, J.P. and
Gachet, C. (1997) FEBS Lett. 403, 26^30.
[7] Savi, P., Laplace, M.C. and Herbert, J.M. (1994) Thromb. Res.
76, 157^169.
[8] Sambrook, J., Fritsh, E.F. and Maniatis, T. (1989) in: Molecular
Cloning. A Laboratory Manual, 2nd edn., Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, NY.
[9] Bouaboula, M., Legoux, P., Pessegue, B., Delpech, B., Dumont,
X., Piechacyk, M., Casellas, P. and Shire, D. (1992) J. Biol.
Chem. 267, 21830^21838.
[10] Born, G.V.R. (1962) Nature 194, 927^929.
[11] Colman, R.W. (1987) in: Modern Methods in Pharmacology
(Colman, R.W., Ed.), Vol. 4. Methods for Studying Platelets
and Megakaryocytes, pp. 33^40, Alan R. Liss, New York.
[12] Meurs, H., Kau¡man, H.F., Koeter, G. and Devries, K. (1980)
Clin. Chim. Acta 106, 91^97.
[13] Grynkiewicz, G., Poenie, M. and Tsien, R.Y. (1985) J. Biol.
Chem. 260, 3440^3450.
[14] Savi, P., Laplace, M.C., Ma¡rand, J.P. and Herbert, J.M. (1994)
J. Pharmacol. Exp. Ther. 269, 772^777.
[15] Janssens, R., Communi, D., Pirotton, S., Samson, M., Parmen-
tier, M. and Boeynaems, J.M. (1996) Biochem. Biophys. Res.
Commun. 221, 588^593.
[16] LeŁon, C., Vial, C., Cazenave, J.P. and Gachet, C. (1996) Gene
171, 295^297.
[17] Ayyanathan, K., Webbs, T.E., Sandhu, A.K., Athwal, R.S., Bar-
nar, E.A. and Kunapuli, S.P. (1996) Biochem. Biophys. Res.
Commun. 218, 783^788.
[18] Boyer, J.L., Romero-Avila, T., Schachter, J.B. and Harden, T.K.
(1996) Mol. Pharmacol. 50, 1323^1329.
[19] O’Brien, J.R. and Heywood, J.B. (1966) J. Clin. Pathol. 19, 148^
153.
[20] Hallam, T.J. and Rink, T.J. (1985) J. Physiol. 368, 131^146.
[21] Haslam, R.J., Davidson, M.M.L. and Desjardins, J.V. (1978)
Biochem. J. 176, 83^95.
[22] Bachelot, C., Cano, E., Grelac, F., Saleun, S., Druker, B.J.,
Levy-Toledano, S., Fischer, S. and Rendu, F. (1992) Biochem.
J. 284, 923^928.
FEBS 19793 5-2-98
P. Savi et al./FEBS Letters 422 (1998) 291^295294
[23] Savi, P., Artcanuthurry, V., Bornia, J., Grelac, F., Maclouf, J.,
Levy-Toledano, S. and Herbert, J.M. (1997) Br. J. Haematol. 97,
185^191.
[24] Mustard, J.F., Packham, M.A., Kinlough-Rathbone, R.L., Perry,
D.W. and Regoeczi, E. (1978) Blood 52, 453^466.
[25] Hallam, T.J., Scrutton, M.C. and Wallis, R.B. (1982) Thromb.
Res. 27, 435^445.
[26] Siess, W. and Lapetina, E. (1989) Biochem. J. 263, 377^385.
[27] Peerschke, E.I. and Zucker, M.B. (1980) Thromb. Haemost. 43,
58^60.
[28] Rink, T.J., Smith, S.W. and Tsien, R.Y. (1982) FEBS Lett. 148,
21^26.
[29] Savi, P., Bornia, J., Salel, V., Delfaud, M. and Herbert, J.M.
(1997) Br. J. Haematol. 98, 880^886.
[30] Ohlmann, P., Laugwitz, K.L., Nurnberg, B., Spicher, K., Schultz,
G., Cazenave, J.P. and Gachet, C. (1995) Biochem. J. 312, 775^
779.
FEBS 19793 5-2-98
P. Savi et al./FEBS Letters 422 (1998) 291^295 295
